Modulation of interleukin-23 signaling with guselkumab in biologic-naive patients versus tumor necrosis factor inhibitor–inadequate responders with active psoriatic arthritis by Siebert, S, Coates, LC, Schett, G, Raychaudhuri, SP, Chen, W, Gao, S, Seridi, L, Chakravarty, SD, Shawi, M, Lavie, F, Sharaf, M, Zimmermann, M, Kollmeier, AP, Xu, XL, Rahman, P, Mease, PJ, Deodhar, A

Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis by Siebert, S, Coates, LC, Schett, G, Raychaudhuri, SP, Chen, W, Gao, S, Seridi, L, Chakravarty, SD, Shawi, M, Lavie, F, Sharaf, M, Zimmermann, M, Kollmeier, AP, Xu, XL, Rahman, P, Mease, PJ, Deodhar, A